Anacor Pharmaceuticals Company Profile (NASDAQ:ANAC)

About Anacor Pharmaceuticals

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.

Industry, Sector and Symbol:

Sector: Healthcare
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: ANAC
CUSIP: 03242010

Key Metrics:

Previous Close: $99.20
50 Day Moving Average: $93.23
200 Day Moving Average: $81.52
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -162.62
P/E Growth: 0.00
Market Cap: $N/A

Additional Links:

Companies Related to Anacor Pharmaceuticals:

Consensus Ratings for Anacor Pharmaceuticals (NASDAQ:ANAC) (?)

Ratings Breakdown:	2 Hold Ratings, 2 Buy Ratings
Consensus Rating:	Buy (Score: 2.50)
Consensus Price Target:	$101.17 (1.98% upside)

Analysts' Ratings History for Anacor Pharmaceuticals (NASDAQ:ANAC)

Show:

Date	Firm	Action	Rating	Price Target
5/18/2016	Mizuho	Downgrade	Buy -> Neutral	$98.00 -> $99.25
5/16/2016	Jefferies Group	Reiterated Rating	Buy
5/16/2016	Wedbush	Downgrade	Outperform -> Neutral	$148.00 -> $99.25
5/10/2016	Cowen and Company	Reiterated Rating	Buy
9/9/2015	JMP Securities	Initiated Coverage	Outperform	$173.00
7/21/2015	Bank of America Corp.	Upgrade	Neutral -> Buy
7/21/2015	Goldman Sachs Group Inc.	Upgrade	Neutral -> Buy	$195.00

(Data available from 9/24/2014 forward)

Earnings History for Anacor Pharmaceuticals (NASDAQ:ANAC)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/4/2016
5/10/2016	Q116	($0.35)	($0.36)	$19.53 million	$17.54 million	View	Listen
2/29/2016	Q415	($0.30)	($0.43)	$27.93 million	$21.20 million	View	Listen
11/3/2015	Q315	($0.23)	($0.37)	$25.60 million	$24.60 million	View	Listen
8/6/2015	Q215	($0.32)	($0.30)	$18.55 million	$21.30 million	View	N/A
5/6/2015	Q115	($0.49)	($0.30)	$9.20 million	$15.26 million	View	N/A
3/12/2015	Q414	($0.61)	($0.24)	$4.74 million	$9.60 million	View	N/A
11/6/2014	Q314	($0.66)	($0.74)	$3.67 million	$3.96 million	View	N/A
8/7/2014	Q214	($0.63)	($0.58)	$3.03 million	$2.90 million	View	N/A
5/7/2014	Q114	($0.39)	($0.51)	$2.82 million	$4.15 million	View	N/A
3/13/2014	Q413	($0.39)	$3.01	$2.85 million	$8.50 million	View	N/A
11/7/2013	Q313	($0.39)	($0.41)	$2.57 million	$3.60 million	View	N/A
8/8/2013	Q2 2013	($0.39)	($0.36)	$2.60 million	$3.40 million	View	N/A
5/9/2013	Q1 2013	($0.39)	($0.42)	$2.57 million	$1.71 billion	View	N/A
3/14/2013	Q4 2012	($0.45)	($0.36)	$3.25 million	$3.28 million	View	N/A
11/7/2012	Q312	($0.45)	($0.46)	$3.18 million	$2.47 million	View	N/A
8/9/2012		($0.45)	($0.47)			View	N/A
5/10/2012		($0.44)	($0.48)			View	N/A
3/13/2012		($0.35)	($0.52)			View	N/A
11/10/2011		($0.41)	($0.16)			View	N/A
8/11/2011		($0.45)	($0.54)			View	N/A
5/5/2011		($0.31)	($0.49)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Anacor Pharmaceuticals (NASDAQ:ANAC)

Current Year EPS Consensus Estimate: $-1.58 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($0.45)	($0.30)	($0.38)
Q2 2016	2	($0.41)	($0.36)	($0.39)
Q3 2016	2	($0.44)	($0.33)	($0.39)
Q4 2016	2	($0.74)	($0.53)	($0.64)
Q1 2017	1	($0.53)	($0.53)	($0.53)
Q2 2017	1	$0.52	$0.52	$0.52
Q3 2017	1	$1.32	$1.32	$1.32
Q4 2017	1	$1.67	$1.67	$1.67

(Data provided by Zacks Investment Research)

Dividend History for Anacor Pharmaceuticals (NASDAQ:ANAC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Anacor Pharmaceuticals (NASDAQ:ANAC)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
6/1/2016	Graeme Bell	CFO	Sell	751	$99.28	$74,559.28
5/23/2016	Keith R Leonard	Director	Sell	9,000	$99.70	$897,300.00
5/16/2016	Anders D Hove	Director	Sell	353,881	$99.59	$35,243,008.79
4/29/2016	Ryan T Sullivan	EVP	Sell	3,125	$66.33	$207,281.25
4/8/2016	Anders D Hove	Director	Sell	229,301	$71.10	$16,303,301.10
3/22/2016	Paul L Berns	CEO	Sell	37,500	$60.31	$2,261,625.00
1/19/2016	Vincent P. Ippolito	EVP	Sell	20,000	$95.41	$1,908,200.00
1/15/2016	Lee Zane	SVP	Sell	1,466	$89.57	$131,309.62
1/4/2016	Paul L. Berns	CEO	Sell	2,533	$112.35	$284,582.55
1/4/2016	Ryan T. Sullivan	VP	Sell	733	$111.78	$81,934.74
1/4/2016	Vincent P. Ippolito	EVP	Sell	855	$112.28	$95,999.40
12/11/2015	Paul L. Berns	CEO	Sell	20,000	$117.26	$2,345,200.00
12/10/2015	Ryan T. Sullivan	VP	Sell	10,000	$110.41	$1,104,100.00
9/15/2015	Lee Zane	SVP	Sell	14,000	$139.84	$1,957,760.00
9/15/2015	Paul L. Berns	CEO	Sell	20,000	$139.83	$2,796,600.00
8/13/2015	Paul L Berns	CEO	Sell	20,000	$138.69	$2,773,800.00
6/15/2015	Lee Zane	SVP	Sell	12,000	$69.05	$828,600.00
5/15/2015	Jacob J Plattner	VP	Sell	8,920	$63.73	$568,471.60
5/14/2015	Carmen R Rodriguez	VP	Sell	61,942	$62.73	$3,885,621.66
4/29/2015	Ryan T Sullivan	VP	Sell	3,125	$53.61	$167,531.25
4/27/2015	Paul L Berns	CEO	Sell	50,000	$63.64	$3,182,000.00
4/15/2015	Jacob J Plattner	VP	Sell	8,920	$62.81	$560,265.20
3/23/2015	Geoffrey M Parker	CFO	Buy	3,000	$52.43	$157,290.00
3/16/2015	Jacob J Plattner	VP	Sell	8,920	$55.60	$495,952.00
3/16/2015	Lee Zane	SVP	Sell	12,000	$56.44	$677,280.00
3/4/2015	Sanjay Chanda	SVP	Sell	5,000	$45.00	$225,000.00
3/3/2015	Vincent P Ippolito	EVP	Sell	9,000	$43.88	$394,920.00
3/2/2015	Jacob J Plattner	VP	Sell	6,875	$44.02	$302,637.50
3/2/2015	Kirk R Maples	SVP	Sell	600	$43.95	$26,370.00
1/2/2015	Jacob J Plattner	VP	Sell	6,875	$32.09	$220,618.75
12/26/2014	Paul L Berns	CEO	Sell	25,000	$30.82	$770,500.00
12/12/2014	Lucy Shapiro	Director	Sell	289,685	$35.11	$10,170,840.35
12/11/2014	Lee Zane	SVP	Sell	4,900	$36.09	$176,841.00
12/9/2014	Kirk R Maples	SVP	Sell	60,000	$36.52	$2,191,200.00
12/1/2014	Jacob J Plattner	VP	Sell	6,875	$33.34	$229,212.50
12/1/2014	Kirk R Maples	SVP	Sell	600	$33.38	$20,028.00
11/26/2014	Sanjay Chanda	SVP	Sell	5,000	$35.00	$175,000.00
11/3/2014	Jacob J Plattner	VP	Sell	6,875	$29.32	$201,575.00
10/1/2014	Jacob J Plattner	VP	Sell	6,875	$24.47	$168,231.25
9/26/2014	Anders D Hove	Director	Sell	20,000	$25.00	$500,000.00
9/19/2014	Anders D Hove	Director	Sell	740,000	$24.87	$18,403,800.00
9/16/2014	Anders D Hove	Director	Sell	90,000	$24.99	$2,249,100.00
9/10/2014	Sanjay Chanda	SVP	Sell	10,000	$24.25	$242,500.00
9/8/2014	Geoffrey M Parker	CFO	Buy	6,590	$21.82	$143,793.80
8/27/2014	Mark Leschly	Director	Sell	13,067	$22.50	$294,007.50
5/20/2014	Kirk Maples	SVP	Sell	1,500	$14.15	$21,225.00
4/21/2014	Kirk Maples	SVP	Sell	1,500	$15.60	$23,400.00
3/24/2014	Geoffrey Parker	CFO	Buy	5,000	$20.11	$100,550.00
3/21/2014	Lucy Shapiro	Director	Sell	80,000	$21.14	$1,691,200.00
3/20/2014	Kirk Maples	SVP	Sell	3,000	$22.39	$67,170.00
3/18/2014	Geoffrey Parker	CFO	Buy	2,410	$22.60	$54,466.00
3/5/2014	David Perry	CEO	Sell	65,000	$20.22	$1,314,300.00
2/20/2014	Kirk Maples	SVP	Sell	3,000	$19.33	$57,990.00
2/5/2014	David Perry	CEO	Sell	15,000	$17.00	$255,000.00
1/21/2014	Kirk Maples	SVP	Sell	3,000	$20.27	$60,810.00
1/9/2014	David Perry	CEO	Sell	65,000	$16.32	$1,060,800.00
12/9/2013	David Perry	CEO	Sell	40,328	$16.23	$654,523.44
11/26/2013	Geoffrey Parker	CFO	Buy	10,000	$13.40	$134,000.00
11/25/2013	Geoffrey Parker	CFO	Buy	10,000	$12.85	$128,500.00
8/14/2013	Kirk Maples	SVP	Sell	1,052	$9.71	$10,214.92
8/13/2013	Geoffrey Parker	CFO	Buy	50,000	$8.34	$417,000.00
6/19/2013	Geoffrey M Parker	CFO	Buy	23,046	$5.20	$119,839.20
6/18/2013	Geoffrey M Parker	CFO	Buy	20,000	$5.22	$104,400.00
6/14/2013	Kirk R Maples	SVP	Sell	5,600	$5.39	$30,184.00
11/26/2012	Kirk R Maples	SVP	Sell	3,000	$5.22	$15,660.00
11/1/2012	Kirk R Maples	SVP	Sell	3,000	$5.81	$17,430.00
10/5/2012	Lucy Shapiro	Director	Sell	30,000	$6.67	$200,100.00
8/22/2012	Geoffrey M Parker	CFO	Buy	5,000	$6.19	$30,950.00

(Data available from 1/1/2013 forward)

Latest Headlines for Anacor Pharmaceuticals (NASDAQ:ANAC)

Date	Headline
	Allergan to buy three companies for combined $2.4 billion (NASDAQ:ANAC) www.wacotrib.com - September 24 at 8:48 AM
	Dermata Therapeutics, LLC Announced the Addition of Wendell ... - PR Newswire (press release) (NASDAQ:ANAC) www.prnewswire.com - September 21 at 4:25 PM
	Anacor Pharmaceuticals Inc (ANAC) CFO Graeme Bell Sells 751 Shares - DailyQuint (NASDAQ:ANAC) dailyquint.com - September 21 at 4:25 PM
	Anacor Pharmaceuticals, Inc. Pipeline Review, Industry Analysis, Size and Clinical trial 2016 - 2020 - Medgadget (blog) (NASDAQ:ANAC) www.medgadget.com - September 21 at 4:25 PM
	Dermatology Grand Rounds (NASDAQ:ANAC) planitpurple.northwestern.edu - September 21 at 9:22 AM
	Dermata Therapeutics, LLC Announced the Addition of Wendell Wierenga, Ph.D. to its Board of Directors (NASDAQ:ANAC) finance.yahoo.com - September 20 at 9:23 AM
	Weekly Research Analysts' Ratings Updates for Anacor Pharmaceuticals (ANAC) - DailyQuint (NASDAQ:ANAC) dailyquint.com - September 17 at 3:31 PM
	What To Keep In Mind As Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Goes To Allergan - Scibility Media (NASDAQ:ANAC) scibilitymedia.com - September 16 at 3:28 PM
	Better Buy: Pfizer Inc. vs. AbbVie Inc. - Motley Fool (NASDAQ:ANAC) www.fool.com - September 15 at 3:29 PM
	Allergan to Buy Vitae Pharmaceuticals for $639 Million - Wall Street Journal (NASDAQ:ANAC) www.wsj.com - September 14 at 3:29 PM
	Brokers Update Target Prices On Anacor Pharmaceuticals, Inc. (ANAC) - National Daily Press (NASDAQ:ANAC) www.nationaldailypress.com - September 13 at 8:19 AM
	Gilead Sciencs, Inc. a Takeover Target? It's Not as Crazy As It Sounds - Motley Fool (NASDAQ:ANAC) www.fool.com - September 12 at 8:19 AM
	Mondelez and Reynolds Boast Fat Profit Margins - Virginian-Pilot (NASDAQ:ANAC) pilotonline.com - September 10 at 3:28 PM
	Global Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): North America Expected to Account … (NASDAQ:ANAC) finance.yahoo.com - September 10 at 8:16 AM
	Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC): What is the Sell-side Making of this Stock? - Post News (NASDAQ:ANAC) www.kentuckypostnews.com - September 9 at 8:17 AM
	Placing Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) Shares Under the Microscope - National Daily Press (NASDAQ:ANAC) www.nationaldailypress.com - September 9 at 8:17 AM
	On Investments: Profit margins can offer hint that a stock is strong - Omaha World-Herald (NASDAQ:ANAC) www.omaha.com - September 7 at 12:27 PM
	Dorfman: Fat profit margins can be sign of great stock - Tribune-Review (NASDAQ:ANAC) triblive.com - September 6 at 8:16 AM
	Seizures Pipeline H2 2016 Market Review Research Report - MarketWatch (NASDAQ:ANAC) www.marketwatch.com - September 2 at 8:10 AM
	Seizures Pipeline H2 2016 Market Review Research Report - Yahoo Finance (NASDAQ:ANAC) finance.yahoo.com - September 1 at 3:31 PM
	What Investors Should Know about the Pfizer-Anacor Deal (NASDAQ:ANAC) marketrealist.com - August 29 at 4:08 PM
	Game On for Pfizer With $14 Billion Medivation Buyout (or, Why ... - Madison.com (NASDAQ:ANAC) host.madison.com - August 27 at 3:29 PM
	Pfizer-Anacor Deal Completed in June 2016 (NASDAQ:ANAC) marketrealist.com - August 26 at 11:39 AM
	Why Pfizer's Acquisition of Anacor Is a Great Fit (NASDAQ:ANAC) www.fool.com - August 26 at 11:39 AM
	Pfizer deal highlights US Pharma trend for targeted M&A: Fitch (NASDAQ:ANAC) www.indiainfoline.com - August 25 at 8:17 AM
	Pfizer makes 2nd acquisition in week with AstraZeneca deal (NASDAQ:ANAC) triblive.com - August 25 at 8:17 AM
	Pfizer to buy US cancer drug company for $14 billion (NASDAQ:ANAC) www.enca.com - August 24 at 11:47 AM
	Write A Prescription For More Pharma M&A With This ETF (NASDAQ:ANAC) money.cnn.com - August 24 at 11:47 AM
	Pfizer Makes Cancer Play With Medivation Deal (NASDAQ:ANAC) myhealthbowl.com - August 23 at 7:46 AM
	Pfizer buys Medivation for $14 bn to boost cancer drug roster (NASDAQ:ANAC) economictimes.indiatimes.com - August 23 at 7:46 AM
	Pfizer to buy Medivation in $14-billion deal (NASDAQ:ANAC) www.thehindu.com - August 23 at 7:46 AM
	Pfizer boosts cancer drug roster with $14B Medivation deal (NASDAQ:ANAC) www.foxnews.com - August 23 at 7:46 AM
	Can the Crowd & Analysts Agree on Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC)? - Post News (NASDAQ:ANAC) www.kentuckypostnews.com - August 21 at 8:15 AM
	Why Pfizer's Acquisition of Anacor Is a Great Fit -- The Motley Fool - Motley Fool (NASDAQ:ANAC) www.fool.com - August 20 at 8:31 AM
	Activist Keith Meister Unloads Large Pfizer (PFE) Position, Takes Stakes in B/E Aerospace (BEAV), Johnson Controls ... - Insider Monkey (blog) (NASDAQ:ANAC) www.insidermonkey.com - August 18 at 3:37 PM
	Why Pfizer's Acquisition of Anacor Is a Great Fit - Madison.com (NASDAQ:ANAC) host.madison.com - August 18 at 3:37 PM
	Bay Area M&A activity drives new startup growth (NASDAQ:ANAC) www.bizjournals.com - August 12 at 12:05 PM
	3 Healthcare Stocks Poised to Beat Q2 Earnings - Yahoo Finance (NASDAQ:ANAC) finance.yahoo.com - August 11 at 12:42 PM
	Global Atopic Dermatitis Treatment Market to be Driven by Introduction of New Products (NASDAQ:ANAC) www.openpr.com - August 10 at 3:49 PM
	Dermatophytic Onychomycosis Therapeutics Market Current Scenario Analysis (NASDAQ:ANAC) www.sbwire.com - August 5 at 11:54 AM
	New drugs help Pfizer to get well (NASDAQ:ANAC) www.nashuatelegraph.com - August 3 at 12:04 PM
	Pfizer Still Examining Breakup While Analysts See Lower Odds (NASDAQ:ANAC) www.bloomberg.com - August 2 at 3:32 PM
	Pfizer beats Street 2Q forecasts despite big drop in profit (NASDAQ:ANAC) www.starherald.com - August 2 at 3:32 PM
	PFIZER REPORTS SECOND-QUARTER 2016 RESULTS (NASDAQ:ANAC) www.enhancedonlinenews.com - August 2 at 8:15 AM
	Will Pfizer Book Another Healthy Quarter? (NASDAQ:ANAC) www.thestreet.com - August 1 at 3:28 PM
	2016 Global Onychomycosis (Tinea Unguium) Drug Market Professional Survey (NASDAQ:ANAC) www.medgadget.com - August 1 at 8:25 AM
	Stock to Watch: Price Target and Company Rating Review for Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) - TGP (NASDAQ:ANAC) telanaganapress.com - July 22 at 3:29 PM
	How Many Anacor Pharmaceuticals Inc (NASDAQ:ANAC)'s Analysts Are Bearish? - Press Telegraph (NASDAQ:ANAC) presstelegraph.com - July 21 at 9:04 PM
	Now Available: Anacor Pharmaceuticals, Inc. (ANAC) - Financial and Strategic SWOT Analysis Review (NASDAQ:ANAC) www.live-pr.com - July 20 at 11:36 AM
	Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:ANAC) www.engelwooddaily.com - July 19 at 3:29 PM